Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04677829
Recruitment Status : Recruiting
First Posted : December 21, 2020
Last Update Posted : May 10, 2022
Sponsor:
Collaborator:
United States Department of Defense
Information provided by (Responsible Party):
Pinteon Therapeutics, Inc

Brief Summary:
This is a Phase 1, multi-center, randomized, double-blind, placebo-controlled, multiple-ascending- dose trial to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of intravenous PNT001 in hospitalized patients with traumatic brain injury.

Condition or disease Intervention/treatment Phase
Traumatic Brain Injury Biological: PNT001 Biological: %5 dextrose for infusion Phase 1

Detailed Description:

The Phase 1 study is a double-blind, multiple ascending dose trial evaluating a total of 64 patients across two dose cohort groups. Each cohort will include 32 patients (24 active; 8 placebo) who will be randomized to receive three doses of either PNT001 or placebo. Doses studied will be 1000mg and 4000mg.

Patients admitted to the trauma center who meet entrance criteria will receive their first dose of study drug within 24 hours of documented TBI. They will remain in the facility for at least 24 hours after initial dose. Baseline biomarker collection and cognitive assessments will be completed. Study medication will be administered as an IV infusion over 30 minutes (for 1000mg cohort) or 60 minutes (for 4000mg cohort) followed by collection of safety, tolerability, pharmacokinetic, biomarker, imaging, and cognitive data over 12 weeks. Subsequent dosing visits will be at Days 28 and 56. All visits after initial discharge will be on an outpatient basis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 64 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Escalating dose level cohorts; each cohort with an active and a placebo arm
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Study drug will be administered and assessed in double-blinded fashion.
Primary Purpose: Treatment
Official Title: Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Trial to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Intravenous PNT001 in Hospitalized Patients With Traumatic Brain Injury (TBI)
Actual Study Start Date : March 29, 2021
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : January 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: PNT001 1000mg
PNT001 diluted in 5% dextrose for infusion
Biological: PNT001
30 minute infusion for PNT001 1000mg; 60 minute infusion for PNT001 4000mg

Experimental: PNT001 4000mg
PNT001 diluted in 5% dextrose for infusion
Biological: %5 dextrose for infusion
30 min placebo infusion for 1000mg; 60 minute placebo infusion for 4000mg

Placebo Comparator: Placebo
5% dextrose for infusion
Biological: PNT001
30 minute infusion for PNT001 1000mg; 60 minute infusion for PNT001 4000mg

Biological: %5 dextrose for infusion
30 min placebo infusion for 1000mg; 60 minute placebo infusion for 4000mg




Primary Outcome Measures :
  1. Incidence of Treatment Emergent Adverse Events [ Time Frame: 84 day study duration ]
    assess adverse events

  2. Incidence of Treatment Emergent Clinical Laboratory Test Abnormalities [ Time Frame: 84 day study duration ]
    measure clinical laboratory values

  3. Incidence of Treatment Emergent Abnormalities in Physical Examination Findings [ Time Frame: 84 day study duration ]
    perform physical examination

  4. Incidence of Treatment Emergent Abnormalities in Neurological Examination Findings [ Time Frame: 84 day study duration ]
    perform neurological examination

  5. Incidence of Treatment Emergent Abnormalities in Vital Signs [ Time Frame: 84 day study duration ]
    assess blood pressure, pulse, temperature, respiratory rate

  6. Incidence of Treatment Emergent Abnormalities in 12-lead Electrocardiogram Assessment [ Time Frame: 84 day duration of study ]
    measure ECG parameters


Secondary Outcome Measures :
  1. Pharmacokinetic Properties of PNT001 in Serum [ Time Frame: 84 day duration of study ]
    measure concentration of PNT001 in serum


Other Outcome Measures:
  1. Anti-Drug Antibodies (ADA) [ Time Frame: 84 day duration of study ]
    number of participants with presence of anti-drug antibodies (ADA) in serum

  2. Biomarker Measurements in Plasma [ Time Frame: 84 day duration of study ]
    measure concentrations of total (mid-domain) tau, NfL, GFAP, UCH-L1, pT181 tau, pT231 tau total tau in plasma

  3. Effects of PNT001 on imaging parameters [ Time Frame: Day 3 through the remainder of the 84 day study ]
    measure diffusion tensor imaging parameters

  4. Effects of PNT001 on cognitive measures [ Time Frame: 84 day duration of study ]
    scores on the Trails A and B assessments

  5. Effects of PNT001 on health related Quality of Life [ Time Frame: 84 day duration of the study ]
    measure change in ratings across 8 categories on the NeuroQOL assessment

  6. Effects of PNT001 on a Global Outcome Scale [ Time Frame: 84 day duration of the study ]
    measure disability outcome based on ratings in 8 areas of the Global Outcome Scale Extended (GOSE)

  7. hsCRP Measurement in Serum [ Time Frame: 84 day duration of the study ]
    measure concentrations of hsCRP in serum



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Hospitalization due to documented evidence of TBI with Glasgow Coma Scale (GCS) Score 9-12 or GCS score of 13-15 with radiographic evidence of trauma.
  2. Duration from documented time of TBI event to time of start of initial dose of study drug will not exceed 24 hours.
  3. Signed informed consent by patient, or where applicable, patient's legally authorized representative.
  4. Male and females, 18- 65 years of age at time of screening (State's legal age of majority is minimum age if higher than 18).
  5. Female patients must meet protocol defined criteria for 1) non-childbearing potential, 2) post menopausal or 3) must have a negative pregnancy test and agree to contraception as outlined in the protocol.
  6. Male must agree to use acceptable contraception and refrain from sperm donation during the entire study and for 200 days after dosing has been completed.
  7. Has not participated in a clinical drug trial within 3 months of study start.
  8. Body Mass Index (BMI) of 18.5-35.0 kg/m2 and for the 4000mg dose group only, weight greater than or equal to 44.8 kg.
  9. Vision, hearing, speech, motor function, and comprehension sufficient for compliance with all testing procedures and assessments.

Exclusion Criteria:

  1. TBI that does not require hospitalization.
  2. TBI outside 24-hour window.
  3. GCS < 9 within 2 hours of dosing.
  4. History of TBI in past 12 months that resulted in patient seeking medical attention.
  5. Evidence of penetrating head trauma or depressed skull fracture.
  6. Clinical or radiographic evidence of mass effect, midline shift, or intracranial hypertension, requiring craniotomy/craniectomy.
  7. Evidence of symptomatic cervical, thoracic, lumbar spine injury e.g. paresis, radiculopathy, that can be localized to the injury.
  8. Systemic traumatic injury that would preclude participation in study or is expected to result in long-term disability.
  9. Any other acute or chronic medical illness that in the judgement of the study physician results in functional impairment or impairs neuropsychiatric function.
  10. Any acute intoxication that in the judgement of the study physician results in significant functional impairment or impairs neuropsychiatric function.
  11. Any history of cancer within 5 years of enrollment with the exception of resected skin basal cell carcinoma.
  12. Any major surgery requiring general anesthesia within 4 weeks of study drug administration.
  13. Donation of blood or serum ≥500 mL to a blood bank or in a clinical study (except screening visit) within 3 months of study drug administration.
  14. Known recent (within 6 months of study drug administration) drug or alcohol abuse as defined in DSM V, Diagnostic Criteria for Drug and Alcohol Abuse.
  15. Evidence of any clinically significant neurological or psychiatric disorder that could interfere with study assessments as determined by investigator and sponsor.
  16. Patient has history or currently has schizophrenia, schizoaffective disorder or bipolar disorder, untreated major depression (DSM-V or ICD-10 criteria).
  17. Significant illness within the prior 30 days.
  18. Abnormalities in creatinine, hepatic transaminases, or QT that would preclude entry into the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04677829


Contacts
Layout table for location contacts
Contact: Wendy Luca, MSN 860-319-9938 wluca@pinteon.com

Locations
Layout table for location information
United States, California
University of California Irvine Medical Center Recruiting
Orange, California, United States, 92868
Contact: Leonid Groysman, MD       lgroysma@hs.uci.edu   
Principal Investigator: Leonid Groysman, MD         
United States, Florida
University of Miami -Jackson Health System Not yet recruiting
Miami, Florida, United States, 33136
Contact: Leticia Fisher    305-243-3056      
United States, Iowa
University of Iowa Recruiting
Iowa City, Iowa, United States, 52242
Contact: Bryan Wilson, MD       brian-wilson@uiowa.edu   
Principal Investigator: Bryan Wilson, MD         
United States, New York
North Shore University Hospital Recruiting
Manhasset, New York, United States, 11030
Contact: Betsy Moclair    516-253-7753    bmoclair@northwell.edu   
Principal Investigator: Jamie Ullman, MD         
United States, North Carolina
Vidant Medical Center Recruiting
Greenville, North Carolina, United States, 27834
Contact: Kenneth Lee, MD    252-847-1550      
United States, Ohio
Miami Valley Hospital Not yet recruiting
Dayton, Ohio, United States, 45409-2722
Contact: Gregory Semon    937-208-8322    gregory.semon@wrightstatephysicians.org   
United States, Pennsylvania
Penn Presbyterian Medical Center Recruiting
Philadelphia, Pennsylvania, United States, 19104
Principal Investigator: Ramon Diaz-Arrastia, MD, PhD         
Sponsors and Collaborators
Pinteon Therapeutics, Inc
United States Department of Defense
Investigators
Layout table for investigator information
Study Director: Larry Altstiel, MD, PhD Pinteon Therapeutics
Layout table for additonal information
Responsible Party: Pinteon Therapeutics, Inc
ClinicalTrials.gov Identifier: NCT04677829    
Other Study ID Numbers: PNT001-002
First Posted: December 21, 2020    Key Record Dates
Last Update Posted: May 10, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Injuries
Brain Injuries, Traumatic
Wounds and Injuries
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System